<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777216</url>
  </required_header>
  <id_info>
    <org_study_id>167CLP</org_study_id>
    <nct_id>NCT02777216</nct_id>
  </id_info>
  <brief_title>ConfidenHT System for Diagnostic Electrical Mapping of Renal Nerves</brief_title>
  <acronym>RDN</acronym>
  <official_title>ConfidenHTTM System Safety and Performance of Diagnostic Electrical Mapping of Renal Nerves in Hypertensive Patients and/or Potential Candidates for a Renal Sympathetic Denervation (RDN) Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pythagoras Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rainbow Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the ConfidenHT System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and performance of the ConfidenHT System for diagnostic mapping of
      renal nerves; functional distribution of renal nerves and the effect of renal nerve
      stimulation on the blood pressure
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of serious adverse events (system and/or procedure related events)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ConfidenHT system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ConfidenHT system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ConfidenHT system</intervention_name>
    <description>ConfidenHT Medical system</description>
    <arm_group_label>ConfidenHT system</arm_group_label>
    <other_name>ConfidenHT Medical system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Age &gt;18 years and &lt;75.

          3. Either:

               1. Hypertensive patients planned to undergo elective cardiac catheterization

               2. Potential candidates for renal sympathetic denervation

          4. Main renal artery with diameter ≥ 4.0mm.

          5. Glomerular Filtration Rate (GFR) &gt;45 mL/min

          6. A patient who is mentally competent with the ability to understand and comply with
             the requirements of the study.

          7. The patient agrees to attend all follow-up evaluations and is willing to complete
             required exams and tests.

          8. Female patients with childbearing potential must agree:

               -  to use a valid method of contraception (oral contraceptives, intrauterine
                  device, subcutaneous contraceptive implant, vaginal ring)

               -  to perform a pregnancy test

        Exclusion criteria:

          1. Previous participation in another study with any investigational drug or device
             within the past 30 days.

          2. Relevant renal artery disease (% diameter stenosis&gt;30%, aneurysm or fibromuscular
             dysplasia).

          3. Known secondary causes of hypertension.

          4. The patient has a life expectancy ≤ 12 months.

          5. The patient has undergone prior renal denervation, renal stenting, and/or abdominal
             aortic stent grafts.

          6. The patient has chronic oxygen use other than nocturnal support for sleep apnea.

          7. The patient has type I diabetes mellitus.

          8. The patient has had a previous organ transplant or is awaiting a renal transplant.

          9. Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal
             stimulator; baroreflex stimulator).

         10. The patient has triple ipsilateral artery ostia.

         11. Moderate to severe valvular heart disease.

         12. The patient has other concomitant conditions that may adversely affect the patient or
             the study outcome.

         13. Female who is pregnant, nursing or planning to become pregnant.

         14. Documented contraindication or allergy to contrast medium not amenable to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kostas Tsioufis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hippocratio Hospital, Athens, Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Raveh Arbel</last_name>
    <phone>972-9531116</phone>
    <email>danara@pythagorasmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hippocratio Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costas Tsioufis, DR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>EMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joost Daemen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michiel Voskuil, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 8, 2016</lastchanged_date>
  <firstreceived_date>May 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RDN</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
